Design and synthesis of dual-ligand modified chitosan as a liver targeting vector

Chen, Houxiang; Li, Min; Wan, Tao; Zheng, Qichang; Cheng, Mingrong; Huang, Shiqi; Wang, Yong

doi:10.1007/s10856-011-4494-1

Cited by 27 publications

(21 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, GA was conjugated to CS via a reaction between the amine group (NH 2 ) of CS and the carboxyl group (COOH) of GA by using 1‐ethyl‐3‐(3‐dimethylaminopropyl) carbodiimide (EDC), and N ‐hydroxysuccinimide (NHS) as activation agents, as described in a previous study . The reaction mechanism of CS–CA synthesis is shown in Figure A.…”

Section: Resultsmentioning

confidence: 99%

Fabrication of Chitosan‐18β‐Glycyrrhetinic Acid Modified Titanium Implants with Nanorod Arrays for Suppression of Osteosarcoma Growth and Improvement of Osteoblasts Activity

Zhang

Cheng

Gong

et al. 2017

Adv Funct Materials

View full text Add to dashboard Cite

Surgery has been combined with chemotherapy to treat osteosarcoma. However, the recovery rate of osteosarcoma patients is still low. To prevent post-operative recurrence of the osteosarcoma, developing an alternative biomaterial is essential. 18β-Glycyrrhetinic acid (GA) has shown potential anticancer activity in various malignancies. Here it is proposed that GA can induce osteosarcoma cell apoptosis, and a polydopamine-mediated titanium oxide nanorod (TiO 2 NR) surface is functionalized by covalently grafting the chitosan-18β-glycyrrhetinic acid conjugate (CS-GA). In vitro and in vivo biological tests indicate that the CS-GA modified surface shows significant antiproliferation and apoptosis in osteosarcoma cells (MG63). Additionally, this modified surface with nanoarray structure stimulation and chitosan supplementation significantly promotes osteoblast (MC3T3-E1) adhesion and proliferation in vitro. This dual-functional, Ti-based implant with balanced antitumor and biocompatibility properties represents an effective strategy for the surgical treatment of osteosarcoma.

show abstract

Section: Resultsmentioning

confidence: 99%

Fabrication of Chitosan‐18β‐Glycyrrhetinic Acid Modified Titanium Implants with Nanorod Arrays for Suppression of Osteosarcoma Growth and Improvement of Osteoblasts Activity

Zhang

Cheng

Gong

et al. 2017

Adv Funct Materials

View full text Add to dashboard Cite

show abstract

“…198,[255][256][257][258][259][260] In our previous report, dualligand Gal moieties and GA-modified chitosan NPs were prepared as a drug or gene carrier for HCC. 261 The cellular uptake in vitro and biodistribution in vivo demonstrates that this dual-ligand decorated nanosystem can enhance the specific recognition and internalization by hepatoma cells, compared with single-ligand decorated nanosystem. Besides, it seems to be another good alternative to modify HA with a small-molecular ligand to further enhance the targeting of HA vehicle.…”

Section: Dual-ligand Modification To Further Enhance Active Targetingmentioning

confidence: 96%

Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma

Li¹,

Zhang²,

Wang³

et al. 2016

IJN

Self Cite

117

View full text Add to dashboard Cite

“…This indicated that Bio-GC/5-FU nanoparticles allowed the delivery of more 5-FU into hepatoma carcinoma cells via the biotin receptor and regulated the complex intracellular signal conduction by 5-FU to achieve significant inhibitory effects on the migration of liver cancer cells [39]. CS, galactose, and biotin have good biological compatibility and degradability, and have no obvious toxic side effects [40][41][42]. We synthesized Bio-GC nanomaterials and tested the toxicity of the Bio-GC nanomaterials.…”

Section: Discussionmentioning

confidence: 99%

Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo

Cheng

Zhi

et al. 2018

Cell Physiol Biochem

Self Cite

View full text Add to dashboard Cite

Background/Aims: Our previous study found that a nanoparticle drug delivery system that operates as a drug carrier and controlled release system not only improves the efficacy of the drugs but also reduces their side effects. However, this system could not efficiently target hepatoma cells. The aim of this study was to synthesize biotin-modified galactosylated chitosan nanoparticles (Bio-GC) and evaluate their characteristics in vitro and in vivo. Methods: Bio-GC nanomaterials were synthesized, and confirmed by fourier transform infrared spectroscopy (FT-IR) and hydrogen-¹ nuclear magnetic resonance (¹H-NMR). The liver position and cancer target property of Bio-GC nanoparticles in vitro and in vivo was tested by confocal laser and small animal imaging system. The characteristics of Bio-GC/5-fluorouracil (5-FU) nanoparticles in vitro and in vivo were explored by cell proliferation, migration and cytotoxicity test, or by animal experiment. Results: Bio-GC nanoparticles were synthesized with biodegradable chitosan as the nanomaterial skeleton with biotin and galactose grafts. Bio-GC was confirmed by FT-IR and ¹H-NMR. Bio-GC/5-FU nanoparticles were synthesized according to the optimal mass ratio for Bio-GC/5-FU (1: 4) and had a mean particle size of 81.1 nm, zeta potential of +39.2 mV, and drug loading capacity of 8.98%. Bio-GC/5-FU nanoparticles had sustained release properties (rapid, steady, and slow release phases). Bio-GC nanoparticles targeted liver and liver cancer cell in vitro and in vivo, and this was confirmed by confocal laser scanning and small animal imaging system. Compared with GC/5-FU nanoparticles, Bio-GC/5-FU nanoparticles showed more specific cytotoxic activity in a dose- and time-dependent manner and a more obvious inhibitory effect on the migration of liver cancer cells. In addition, Bio-GC/5-FU nanoparticles significantly prolonged the survival time of mice in orthotopic liver cancer transplantation model compared with other 5-FU nanoparticles or 5-FU alone. Bio-GC (0.64%) nanomaterial had no obvious cytotoxic effects on cells; thus, the concentration of Bio-GC/5-FU nanoparticles used was only 0.04% and showed no toxic effects on the cells. Conclusion: Bio-GC is a liver- and cancer-targeting nanomaterial. Bio-GC/5-FU nanoparticles as drug carriers have stronger inhibitory effects on the proliferation and migration of liver cancer cells compared with 5-FU in vitro and in vivo.

show abstract

Design and synthesis of dual-ligand modified chitosan as a liver targeting vector

Cited by 27 publications

References 28 publications

Fabrication of Chitosan‐18β‐Glycyrrhetinic Acid Modified Titanium Implants with Nanorod Arrays for Suppression of Osteosarcoma Growth and Improvement of Osteoblasts Activity

Fabrication of Chitosan‐18β‐Glycyrrhetinic Acid Modified Titanium Implants with Nanorod Arrays for Suppression of Osteosarcoma Growth and Improvement of Osteoblasts Activity

Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma

Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo

Contact Info

Product

Resources

About